CEO Peter Guenter’s focus on first- and best-in-class looks like the right strategy as Spanish pharma builds critical mass in dermatology.
Analysts were impressed with Almirall SA’s first-half sales, noting the strong launch of the oral acne antibiotic Seysara in the US. CEO Peter Guenter told Scrip the firm had “executed well on the new, more ambitious agenda” to focus on “meaningful and clinically relevant innovation” in dermatology.
Guenter, who took over as CEO in October 2017, has accelerated and sharpened the company’s focus on dermatology, committing to...
The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.
Paying €90m upfront for rights to generalized pustular psoriasis drug.
In this week's episode: Merck & Co’s Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee’s Phase II eczema win; and a look at India’s wave of licensing.
